Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference – GlobeNewswire (press release)

Posted: August 29, 2017 at 10:41 am

August 29, 2017 07:30 ET | Source: Kura Oncology, Inc.

SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a panel discussion entitled Precision Medicine in Oncology and Next Generation Diagnostics at Citis 12th Annual Biotech Conference, in Boston on September 6, 2017. The panel is scheduled to begin at 1:00 p.m. EDT (10:00 a.m. PDT).

A live audio webcast of the panel discussion will be available in the Investors section of Kura Oncology’s website at http://www.kuraoncology.com, with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The companys pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncologys lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kuras pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the companys website at http://www.kuraoncology.com.

San Diego, California, UNITED STATES

Kura Oncology, Inc. Logo

LOGO URL | Copy the link below

Formats available:

See the rest here:
Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference – GlobeNewswire (press release)

Related Post